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ABSTRACT
OBJECTIVE  Latent autoimmune diabetes in adults (LADA) exhibits  significant clinical heterogeneity but the underlying causes remain unclear. In this study, we aimed to investigate whether age of onset of LADA contributes to the observed clinical heterogeneity by comparing the clinical, metabolic and immunogenetic characteristics between elderly and young LADA patients .
RESEARCH DESIGN AND METHODS  The cross-sectional study included a total of 639 patients with LADA which was further divided into elderly LADA (E-LADA) group (n=148, age of onset ≥ 60 years) and young LADA (Y-LADA) group (n=491, age of onset ＜ 60 years). Age-matched subjects with type 2 diabetes (T2D) were used as control (E-T2D group, n=600; Y-T2D group, n=638). Clinical characteristics, serum autoantibodies and HLA-DQ haplotypes were compared among these groups.
RESULTS  Compared with patients with Y-LADA, patients with E-LADA have better residual beta-cell function and higher level of insulin resistance (both P ＜ 0.01), more metabolic syndrome characteristics, similar proportion of islet autoantibody positivity, and strikingly different HLA-DQ genetic background. In comparison with T2D patients, E-LADA patients tend to have less metabolic syndrome characteristics, comparable C-peptide levels and insulin resistance levels, and share similar HLA-DQ genetic characteristics.
CONCLUSIONS  E-LADA differs phenotypically and genetically from Y-LADA and has a clinical and genetic profile more similar to that of T2D. These features could potentially help physicians better manage patients with E-LADA.
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Diabetes has become a serious urgent public health problem in China at present. One out of every ten Chinese suffers from diabetes, and China has more than 100 millions of adults with diabetes, which is more than any other country in the world (). Latent autoimmune diabetes in adults (LADA) accounts for 3% to 12% of all patients with diabetes, which differs significantly in different ethnic groups (). Our previous study has shown that around 5.9% of diabetic patients were classified as LADA in Chinese (). According to the population epidemiological survey, it can be speculated that China has the largest number of LADA patients, which are more than 6 millions  ADDIN EN.CITE (). Because of its high prevalence, LADA represents an important clinical issue that should be further addressed.
Although LADA appear similar to type 2 diabetes (T2D), the typical presence of islet autoantibodies, such as glutamic acid decarboxylase autoantibody (GADA), protein tyrosine phosphatase antibody (IA-2A), and zinc transporter 8 autoantibody (ZnT8A), indicate an autoimmune basis of LADA with a delayed progression compared with classic type 1 diabetes (). These autoantibodies were valuable for prediction and diagnosis of LADA. Also, genetic factors have been thought to correlate with the development of LADA (). Variable incidence of LADA among different ethnicities is largely attributed to heterogeneous genetics. The majority of the genetic background of LADA is determined by the human leukocyte antigen (HLA) class II DQ and DR genes, which differs significantly from that of type 1 diabetes risk  ADDIN EN.CITE (; ).
Striking heterogeneity has been recently highlighted as a relevant characteristic of LADA. It is well-known that subjects with LADA have differential clinical, metabolic, immunological, and genetic characteristics when compared with type 1 or type 2 diabetic patients  ADDIN EN.CITE (). In this study, we aimed to investigate whether age of onset of LADA contributes to the observed clinical heterogeneity by comparing the clinical, metabolic and immunogenetic characteristics between elderly LADA (E-LADA) patients diagnosed after the onset age of 60 years and young LADA (Y-LADA) before the onset age of 60 years or T2D patients, with the aim of identifying a distinct entity of E-LADA potentially useful in improving the clinical management.

Research design and methods
LADA patients
A total of 639 LADA patients with Chinese Han origin were recruited from June 2006 to January 2015. LADA patients were included in the study if the following criteria were met: ① diagnosis of diabetes based on World Health Organization criteria with disease onset of age ≥ 30 years old; ② positivity of at least one of the islet autoantibodies including GADA, IA-2A, and ZnT8A; ③ noninsulin requirement for > 6 months; and ④ diabetes duration of < 1 year. Exclusion criteria were as follows: ① patients with other forms of diabetes including rapid-onset type 1 diabetes, maturity onset diabetes of the young, secondary diabetes, or T2D; ② diabetes in pregnancy; and ③ malignancy. LADA patients were divided into two groups according to age of onset: elderly LADA (E-LADA) group (onset age ≥ 60 years) and younger LADA (Y-LADA) group (onset age ＜ 60 years). The E-LADA group included 148 patients (71 males and 77 females) with a mean age of 66 (range 60 - 85) while the Y-LADA group had 491 patients (310 males and 181 females) with a mean age of 45 (range 30 - 59).
T2D patients 
A total of 1238 T2D patients with Chinese Han origin (597 males and 641 females) within the same time period were enrolled as diabetes controls. Inclusion criteria for T2D patients included: 1) diagnosis of diabetes (World Health Organization criteria of 1999); 2) age of onset ≥ 30 years old; 3) disease duration within 1 year; and 4) no ketoacidosis in the first 6 months after the diagnosis of diabetes. Exclusion criteria were as follows: 1) positive for one of the islet autoantibodies, 2) secondary diabetes, 3) diabetes in pregnancy and gestational diabetes mellitus, and 4) malignancy. T2D patients were also divided into two groups according to age of onset: elderly T2D (E-T2D) group (onset age ≥ 60 years, n=600) and younger T2D (Y-T2D) group (onset age ＜ 60 years, n=638). 
Control subjects
A group of 1065 healthy subjects were recruited as normal controls as previously described  ADDIN EN.CITE (). All subjects had normal glucose tolerance and no family history of diabetes. Genotyping for HLA-DQA1 and HLA-DQB1 of control subjects were utilized in this study.
Ethics
In accordance with Helsinki guidelines, an informed consent was provided by all subjects who participated in the study. The protocol was approved by the research ethics committee of the Second Xiangya Hospital of Central South University.
Clinical characteristics and biochemical measurements
At admission, anthropometric data including age at disease onset, duration of disease, sex, body weight, height, waist circumference, hip circumference, blood pressure, waist-hip ratio, and body mass index were obtained. Blood samples were collected for measurements of HbA1c and fasting plasma levels of glucose, total cholesterol, triglyceride, low density lipoprotein (LDL) cholesterol, and high density lipoprotein (HDL) cholesterol. Fasting plasma C-peptide and 2-hr postprandial C-peptide levels were determined using the chemiluminescence method. The homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated based on the conventional formula: HOMA-IR = fasting glucose (mmol/l) × fasting insulin (mU/l) / 22.5 ().
Characterization of metabolic syndrome
Overweight and obesity were defined as body mass index ≥ 25 kg/m2 (WHO criteria). Hypertension was defined as systolic blood pressure ≥140, diastolic blood pressure ≥ 90 mmHg, or presently taking antihypertensive medications. Dyslipidemia was defined as serum triglycerides ≥ 1.7 mmol/L, HDL cholesterol ＜ 1.04 mmol/L for men and ＜1.30 mmol/L for women, or current use of medication for hyperlipidemia. Metabolic syndrome was defined using revised National Cholesterol Education Program-Adult Treatment Panel III criteria, involving achievement of three or more of the following: 1) waist circumference ≥ 90 cm (Asian male) or ≥ 80 cm (Asian female); 2) triglyceride ≥ 1.7 mmol/L, 3) HDL cholesterol ＜1.04 mmol/L (male) or ＜ 1.30 mmol/L (female), 4) systolic/diastolic blood pressure ≥ 130/85 mmHg, and 5) fasting plasma glucose ≥ 5.6 mmol/L. 
Determination of serum autoantibodies and genotyping for HLA
GADA, IA-2A and ZnT8A were analyzed by radioligand assay as previously described  ADDIN EN.CITE (; ). All samples were measured in duplicate at the Diabetes Center of Central South University. Genomic DNA was extracted from peripheral blood nucleated cells. Genotype for HLA-DQA1 and HLA-DQB1 was determined by direct DNA sequencing as described previously and the HLA-DQA1-DQB1 haplotypes were constructed using the PHASE program  ADDIN EN.CITE ().
Statistical analysis
Statistical analysis was performed using the IBM SPSS Statistics software (version 20). Normally distributed data were presented as means ± SD. Variables with a skewed distribution were reported as median (interquartile range) and log transformed to approximate normality before analysis. The interquartile range is presented as the 25th percentile and the 75th percentile of the distribution. Theχ2 and Fisher’s exact test, when appropriate, were used to test between group differences for categorical variables. One-way ANOVA was used to compare the means among the groups as appropriate and the pairwise comparison was performed with LSD method. P values were corrected for the number of different HLA-DQ haplotypes tested with Bonferroni correction (denoted as Pc). Significance level α was adjusted for α' = α/n*(n-1)/2 (n=4, groups) in the pairwise rate comparison among four groups. P ＜α = 0.05 or Pc ＜ 0.05 or P ＜α’ was considered significant. 

Results 
Comparative features among four groups 
Clinical, biochemical, and metabolic characteristics of the study participants were shown in Table 1. The proportion of E-LADA patients accounted for  23.2% (148/639) of the entire LADA cohort. Compared with disease duration-matched patients with Y-LADA, patients with E-LADA presented with less male predominance, higher waist circumference, higher systolic blood pressure, lower 2-hr post-prandial blood glucose levels, and HbA1c. E-LADA patients had more frequency of hypertension and overweight and obesity than the Y-LADA group. Compared with patients with both Y-T2D and E-T2D, patients with E-LADA tended to have lower BMI, plasma triglycerides, LDL-cholesterol, lower frequency of low HDL- cholesterol and higher plasma HDL cholesterol. In comparison with Y-T2D, E-LADA patients had higher systolic blood pressure and less frequent metabolic syndrome, but they were not statistically significant compared with E-T2D group.
Clinical characteristics of E-LADA stratified by BMI, GADA titers and FCP
Analysis of the data in E-LADA patients stratified by BMI showed that waist-hip ratio, systolic blood pressure, fasting plasma concentrations of triglyceride, fasting plasma C-peptide (FCP), and 2-hr post-prandial C-peptide levels were higher in higher BMI group (BMI≥ 25.0 kg/m2) than those in leaner group (BMI < 25.0 kg/m2,  all P < 0.05) (Supplementary Table 1). Furthermore, E-LADA patients with high titer of GADA (GADA ≥ 0.3) had lower BMI and plasma concentrations of total cholesterol and LDL-cholesterol, but higher HDL-cholesterol than those with lower GADA titers (all P < 0.05). Further data stratification demonstrated that E-LADA patients with better beta cell function (FCP ＞400 pmol/L) had significantly higher BMI and waistline, more frequency of overweight and obesity, and metabolic syndrome than those with lower FCP (≤ 400 pmol/L), but no differences were found in these metabolic characteristics between E-LADA patients with better beta cell function and E-T2D patients (Fig. 1).
Assessment of islet beta cell function and insulin resistance levels 
To assess islet beta cell function, we determined both fasting and 2-hr postprandial C-peptide levels in study participants. As shown in Fig 2, both fasting and 2-hr post-prandial C-peptide levels were significantly higher in E-LADA patients as compared to Y-LADA patients (both P < 0.01). However, both C-peptide levels in E-LADA group were similar to both E-T2D and Y-T2D groups. E-LADA patients were more insulin resistant than Y-LADA patients as assessed by HOMA-IR. The insulin resistance levels were similar between E-LADA and either E-T2D or Y-T2D. 
E-LADA features according to autoantibodies
Among all E-LADA patients, 88.5% were positive for GADA autoantibody, 23% IA-2A autoantibody, and 21.8% ZnT8A autoantibody. Only 3.8% of patients were positive for all 3 autoantibodies. The frequencies of autoantibody positivity, either alone or in combination, were similar between E-LADA and Y-LADA patients (Supplementary table 2). We further analyzed the titre of GADA in E-LADA patients based on age-group (Fig. 3). E-LADA have more proportion of low titre GADA and low GADA titre compared to Y-LADA age <40 years (both P < 0.01).
Determination of HLA DQA1-DQB1 haplotypes
We have previously identified that certain HLA DQA1-DQB1 haplotypes are involved in the pathogenesis of LADA  ADDIN EN.CITE ()  and as such we compared the HLA DQA1-DQB1 haplotype frequencies in E-LADA patients to those in Y-LADA, T2D, and control subjects (Table 2). Overall LADA patients (including both E-LADA and Y-LADA) had higher frequencies for the DQA1*0102-DQB1*0604, DQA1*0102-DQB1*0201, DQA1*03-DQB1*0401, and DQA1*05-DQB1*0201    haplotypes than control subjects but only higher frequency in DQA1*05-DQB1*0201 than T2D patients (all Pc＜0.001). These differences were attributable to mostly Y-LADA as E-LADA patients only higher frequency in DQA1*0102-DQB1*0604 than controls and no differences in haplotype frequency between E-LADA and T2D. 

Discussion
LADA is probably the most prevalent form of autoimmune diabetes in general (). It is well-known that patients with LADA have remarkably broad clinical, metabolic and genetic characteristics. However, the major characteristic of LADA are mainly focused on three points: presence of islet autoantibodies, age at diagnosis of at least 30 years, and insulin independence for at least 6 months after diagnosis (). Much evidence has shown that a lower body mass index, waist-hip ratio, total cholesterol and triglyceride levels and higher HDL-cholesterol in LADA than those in patients with T2D. The clinical phenotype of patients with LADA also varies substantially with GADA titer. High-titre GADA patients tend to be more similar to classic type 1 diabetes. Low-titre GADA patients are phenotypically more similar to those with T2D (). These differences are also reflected by the metabolic syndrome, which is more prevalent in T2D than LADA, and more prevalent in low-titre than high-titre GADA patients (). These studies have showed LADA exhibited significant clinical heterogeneity.
The present study demonstrates that age of onset of LADA also contributes to the clinical heterogeneity. Patients with E-LADA had significantly more components of metabolic syndrome (higher waist circumference and systolic blood pressure, more frequent hypertension, overweight and obesity) than did those with Y-LADA. However, E-LADA patients tend to have less metabolic syndrome characteristics as compared with T2D patients (lower body mass index, plasma triglyceride and LDL cholesterol, less frequent low HDL cholesterol and metabolic syndrome). These data indicated the characteristics of metabolite profile in E-LADA are intermediate between Y-LADA and T2D.
Previous studies have confirmed that metabolic syndrome is prevalent in LADA patients, however, it is less prevalent compared with T2D patients (). Consistent with this, in our study 58.4% of patients with E-LADA was less prevalent compared with 74.0% of patients with Y-T2D. However, this prevalence was higher than the rate of 41.9% reported in European LADA patients () and the rate of 31.0% reported in another Chinese study  ADDIN EN.CITE (). Generally, obesity and metabolic syndrome have been used as the basis for diagnosis of T2D, but these are very common in the E-LADA population in our study, espicially for the frequency of overweight and obesity, and hypertension, which were similar compared with T2D. Analysis of the data in E-LADA patients stratified by BMI and GADA titre showed that more components of metabolic syndrome was evident in E-LADA patients with low titre of GADA or obesity. It hinted that E-LADA with lean body mass (BMI <25.0 kg/m2) or high titre of GADA should be differently treated compared with that > 25 kg/m2 or low titre of GADA. According to this, it may be suggested that the former should treat with early insulin initiation and the latter should treat likely T2D with metformin. 
Furthermore, the clinical phenotype within E-LADA patients also varies largely depends on islet cell function. E-LADA patients with better fasting C-peptide level have more components of metabolic syndrome and higher prevalence of metabolic syndrome, which are phenotypically more similar to patients with T2D, as compared to patients with worse fasting C-peptide. So we should suggest that we should initiate insulin therapy sooner at least for E-LADA with fasting C-peptide < 400 pmol/L. 
As reported previously, LADA may have a more rapid rate of beta-cell destruction in LADA than in T2D  ADDIN EN.CITE (). A large body of evidence has shown that LADA patients tend to have a more pronounced loss of C-peptide and an increased likelihood of insulin treatment compared with T2D patients  ADDIN EN.CITE (; ; ). In our study, both fasting and 2-hr post-prandial C-peptide levels were significantly higher in E-LADA patients as compared to Y-LADA patients, but were similar to both E-T2D and Y-T2D groups. This observation that patients with E-LADA have better residual beta-cell function in comparison with Y-LADA can be partially explained by the features of GADA that the frequency of high titre GADA in E-LADA is lower than that in Y-LADA. It was showed that high titre GADA was associated with more severe autoimmunity resulting in more prominent traits of insulin deficiency (). We also found that patients with E-LADA displayed more serious insulin resistance level (HOMA-IR) than those with Y-LADA patients but was not significant compared with patients with T2D, making their clinical presentation more similar to T2D. Hence, E-LADA was more similar to T2D than Y-LADA. Previously, Lohmann et al. observed that patients with lower BMI show a more aggressive disease, which can lead to earlier beta-cell exhaustion (). In accordance with this study, we observe that E-LADA patients with lower BMI tend to have a lower fasting C-peptide and 2-hr post-prandial C-peptide levels. These observations indicate that E-LADA patients with leaner physique have poorer residual beta-cell function than patients with a fatter body. 
Currently, the diagnosis of LADA is based on the presence of five major circulating islet autoantibodies including GADA, IA-2A, insulin autoantibody (IAA), islet cell antibody (ICA), and ZnT8A, which also exist in classic type 1 diabetes. Among them, GADA is considered to be the most common, the most sensitive and specific biomarker of LADA (). In the current study, GADA was also the most frequent among the three islet autoantibodies both in E-LADA and Y-LADA patients. Consequently, we recommended that detection of GADA autoantibody alone is necessary when screening for patients with E-LADA. The early diagnosis of E-LADA could be important in determining the most appropriate therapeutic choice in clinical practice. Although the presence of multiple islet-related autoantibodies provided more information than either assay on its own, the frequency of three islet autoantibodies combined was considerably low. In view of this low prevalence of combined autoantibodies, screening for other islet autoantibodies is unlikely to be cost-effective in T2D patients diagnosed after the age of 60 years. Hence, measurement of other islet autoantibodies are not advisable. Previous research has shown that patients with high GADA titers have more severe disease and a greater need of insulin supplementation  ADDIN EN.CITE (). However, our study showed E-LADA have more proportion of low titre GADA and low GADA titre compared to Y-LADA age < 40 years. These may indicate that those patients have an decreased risk of requiring insulin therapy. Taking advantage of previous reports and our results, we strongly recommend the routine clinical detection of GADA in the diagnostic work-up of diabetes mellitus for aged after 60 years.
LADA has been associated with the same genetic features as type 1 diabetes (e.g. HLA class II locus) and T2D (e.g. Transcription factor 7-like 2), which suggest that it may represent a genetic admixture of the two types of diabetes  ADDIN EN.CITE (). However, our previous results suggested that LADA risk conferred by HLA-DRB1-DQA1-DQB1 loci in Chinese differs significantly from that of type 1 diabetes risk  ADDIN EN.CITE (). Our current study showed that DQA1*0102-DQB1*0604 haplotype confer to E-LADA risk but not to Y-LADA susceptibility, while other three LADA associated haplotypes DQA1*0201-DQB1*0201, DQA1*03-DQB1*0401, and DQA1*05-DQB1*0201 which confer Y-LADA susceptibility failed to show evidence for conferring E-LADA susceptibility. Another haplotype DQA1*03-DQB1*0303 also confer to Y-LADA susceptibility but not to E-LADA susceptibility. Horton et al. reported high-risk HLA-DR3/4 genotype associated with age at diagnosis with lower DR3/4 frequency seen in older age in LADA  ADDIN EN.CITE (). Similar with this observation, our results suggest that the E-LADA susceptibility is associated with single HLA-DQ haplotype while Y-LADA susceptibility is associated with multiple HLA-DQ haplotypes. In addition, E-LADA also shares the same HLA-DQ haplotype DQA1*0102-DQB1*0604 with T2D, which raises the question that whether such genetic admixture of E-LADA represents a distinct disease syndrome or is part of an autoimmune continuum. It needs to be further examined in large cohorts of adult-onset autoimmune patients with the genome-wide association studies or whole-genome exome sequencing methods. From the evidence of the HLA-DQ gene, E-LADA making their clinical presentation more similar to T2D can be partly explained by the certain common genetic background that E-LADA may share genetic characteristics with T2D.
In conclusion, patients with E-LADA have better residual beta-cell function, a higher prevalence of metabolic syndrome, similar proportion of islet autoantibodies detection, and strikingly different HLA-DQ gene background as compared with patients with Y-LADA. E-LADA patients tend to have less metabolic syndrome characteristics, comparable C-peptide levels and insulin resistance levels, and sharing a kind of common genetic characteristics in comparison with T2D, making their clinical presentation more similar to T2D. These clinically distinct features could potentially help physicians take better clinical management for these patients with E-LADA. However, it is impossible to accurately distinguish E-LADA from T2D on clinical features because of overlapping for some clinical parameters. Much more researches were required to focus on the characterization of LADA or E-LADA patients. 
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